Epocal, Inc., a leading edge provider of point of care technology, announced that it has received U.S. Food and Drug Administration (FDA) clearance to market its new glucose test on the epoc Blood Analysis System. Glucose measurements are used for the diagnosis and treatment of carbohydrate metabolism disorders including diabetes mellitus and idiopathic hypoglycemia, and of pancreatic islet cell tumors.
Home » Epocal Announces FDA Clearance Of Glucose Test
More recent news
- Think Surgical has first surgical robot cases with Maxx Orthopedics total knee implant
- Wyss Institute affected by Trump’s Harvard funds freeze
- BCI company Paradromics names new chief medical officer
- Intuitive studies highlight positive impact of robotic surgery
- Luma Vision wins FDA clearance for cardiac visualization platform